drugset / Trial / NCT05297760

Intralymphatic Immunotherapy With Polvac Grass & Rye Allergen Extract

NCT05297760 ↗

Phase 1/2 Completed 60 enrolled University of Zurich University of Aarhus · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary goal is to investigate the efficacy of intralymphatic immunotherapy (ILIT) for the treatment of allergic rhinitis and allergic asthma due to sensitisation to grass pollen allergens. 60 patients with allergic rhinitis will be included and randomized to receive either Polvac (n=30) or placebo (n=30). All patients will receive three injections with 4-8 weeks interval. The injections into a inguinal lymph node is guided by sonography. Patients will record symptoms and medication use in the summer of 2022 and 2023.

Timeline

Start
2022-02-10
Primary completion
2025-02-28
Completion
2025-02-28

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Polvac Grass+Rye Unknown — Other